Abstract
The effect of light and bisulfite on infusion solutions containing epinephrine (2 μg/mL), bupivacaine hydrochloride (1 mg/mL), fentanyl (2 μg/mL) and sodium edetate (0.18 μg/mL) was investigated. Solutions were made isotonic using sodium chloride, and they contained either 1.82 μg/mL sodium metabisulfite or no metabisulfite at all. The infusions were stored in polypropylene infusion bags (550 mL) and were subjected to light from a xenon burner with a specter similar to sunlight behind a glass window. The contents of epinephrine, bupivacaine and fentanyl were determined with stability indicating methods using a HPLC system. In two identical experiments epinephrine was demonstrated to be more stable under irradiation in the absence of sodium metabisulfite (89.3% and 91.3% remaining of initial concentration) than in its presence (64.5% and 60.1% remaining). Bupivacaine and fentanyl showed no degradation as a function of light exposure, and the stability was not affected by the presence or absence of bisulfite. After two weeks exposure to natural light (Oslo, 60°N, March) the content of epinephrine was 45.0% of the initial concentration in the solutions containing bisulfite and 95.6% in the solutions without bisulfite (n = 3). The relationship between various concentrations of bisulfite and the photostability of three epinephrine solutions (2 μg/mL, 20 μg/mL and 110 μg/mL) were tested. The results indicated that approximately equimolar concentration of epinephrine compared to bisulfite, or bisulfite in some excess, was least favorable to the stability of epinephrine. A possible explanation for the photodestabilizing effect of bisulfite can be the conversion of superoxide radicals (O2−) to highly reactive hydroxyl radicals (·OH) by bisulfite. From these results it can be concluded that solutions containing epinephrine and bisulfite should be protected from light not only during storage but also during use in cases where the infusion time amounts to several days. An alternative, wherever possible, would be to omit bisulfite in the solutions.
Footnotes
- Received July 15, 1999.
- Accepted December 27, 1999.
- Copyright © Parenteral Drug Association. All rights reserved.
PDA members receive access to all articles published in the current year and previous volume year. Institutional subscribers received access to all content. Log in below to receive access to this article if you are either of these.
If you are neither or you are a PDA member trying to access an article outside of your membership license, then you must purchase access to this article (below). If you do not have a username or password for JPST, you will be required to create an account prior to purchasing.
Full issue PDFs are for PDA members only.
Note to pda.org users
The PDA and PDA bookstore websites (www.pda.org and www.pda.org/bookstore) are separate websites from the PDA JPST website. When you first join PDA, your initial UserID and Password are sent to HighWirePress to create your PDA JPST account. Subsequent UserrID and Password changes required at the PDA websites will not pass on to PDA JPST and vice versa. If you forget your PDA JPST UserID and/or Password, you can request help to retrieve UserID and reset Password below.